Breaking News

You are here » Indian-Commodity  :  Top News  :  Natco's marketing partner Mylan launches generic Glatiramer Acetate in US

05-Oct2017

Natco's marketing partner Mylan launches generic Glatiramer Acetate in US

Natco Pharma's marketing partner Mylan N.V., has launched in the U.S. the first Glatiramer Acetate Injection 40 mg/mL for 3-times-a-week injection that is an AP-rated substitutable generic version of Teva's Copaxone 40 mg/mL, as well as Glatiramer Acetate Injection 20 mg/mL for once-daily injection, an AP-rated, substitutable generic version of Teva's Copaxone 20 mg/mL. These products are indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system. Shipments to customers have commenced.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.


Related News

View all news

Physical rubber prices ruled steady on Saturday

Physical Rubber prices ruled steady on Saturday due to buyer resistance in the market. Spot prices for RSS-4 and RSS-5 variety closed unchanged at Rs 125/ kg and Rs 120.50/ kg respectively.In the futures......

Gold futures trade almost steady on Monday

Gold futures traded almost steady on Monday, with cautious outlook from investors as they eyed on impending report from china showcasing dimmed economic growth to its slowest in 28 years in 2018 in face......

Crude palm oil futures trade in green on rise in demand

Crude palm oil futures traded in green on MCX in line with the firm  trend in Malaysian palm oil prices. Moreover, rise in spot demand from domestic markets coupled with the worries on dip in......

Top News

View all news

Glenmark Pharma recalling 96,240 applicators of its product from US

Glenmark Pharmaceuticals is recalling 96,240 applicators of its product Estradiol vaginal inserts for defective delivery system. The USFDA has termed it as a Class-II recall. The USFDA has classified Class-II......

Infosys hires over 7,600 staff in US

Infosys has hired over 7,600 staff in the US. This hiring is more than three-fourth of its target of recruiting 10,000 American workers. The company is making recruitment from local schools a 'sustained......

SBI to sell 26% stake of SBI payment services

State Bank of India (SBI) is planning to sell 26% stake of its SBI payment services (SPSPL) to Hitachi Payment Services (HPY). After allotment of the shares, SBI shareholding in SPSPL will become 74% from......